Molecular testing is moving to the point of care. Roche said on December 2, 2025 that its cobas liat Bordetella test received FDA 510(k) clearance and a CLIA waiver, with results in about 15 minutes, per the company. On August 6, 2026, Co-Diagnostics announced a dual 510(k) with a concurrent…
NIH's All of Us Research Program became the world's largest …
Three dated milestones define modern research computing for biology: Frontier …
Tandem Health, a Stockholm-based digital health company building an AI …
US bioeconomy policy in September 2026 still has no replacement …
Biotech earnings season is the quarterly window, clustered in late …
A contract research organization is a company that performs research …
Gene synthesis is the industrial process of building specified DNA sequences base by base, without a natural template. Short fragments are made by phosphoramidite chemistry, assembled into genes enzymatically, and error-corrected before sequencing verification, and in the United States…
Epigenetics is the field of study focused on changes in DNA that do not involve alterations to the underlying sequence, per NHGRI's Talking Glossary, which also calls the field epigenomics. The commercial and scientific interest sits in the platforms that read those changes at scale: sequencing-…
Point-of-care testing is diagnostic testing performed at or near the patient, in a physician's office, clinic, or emergency room, rather than a central laboratory, and its legal boundary in the United States is set by CLIA. The FDA categorizes tests as waived, moderate, or high complexity; only…
Total laboratory automation integrates a clinical laboratory's pre-analytical, analytical, and post-analytical phases into connected tracks and systems, per a 2025 review in the Annals of Laboratory Medicine. The review names Abbott, Roche, Siemens, and Beckman Coulter as the companies…
Antibiotic resistance research starts from measurement. The WHO's Global Antimicrobial Resistance and Use Surveillance System reported in October 2025 that one in six laboratory-confirmed bacterial infections worldwide in 2023 was resistant to antibiotic treatment, per the WHO's news release.…
U.S. synthetic DNA biosecurity rests on a voluntary screening framework issued by the Department of Health and Human Services in October 2023, which asks gene synthesis providers and their customers to screen orders for sequences of concern down to 50 nucleotides, per the guidance published by…
Basic research in the United States is funded mainly through competitive grants, cooperative agreements, and fellowships, a structure the National Science Foundation describes as hundreds of funding opportunities across science and engineering. The benchmark instrument is NIH's R01, which the…
BioNTech's supervisory board appointed Guido Oelkers, chief executive of Swedish Orphan Biovitrum since 2017, as the company's next CEO on August 3, 2026, with the transition complete by February 1, 2027 at the latest, per the company. He succeeds co-founder Ugur Sahin, and the chief medical…
Eli Lilly said in May 2026 that it will invest an additional $4.5 billion at two of its three Lebanon, Indiana sites, lifting Indiana capital commitments above $21 billion over six years, per the company's announcement. A December 2025 decision to spend more than $6 billion on an Alabama API…
A conference abstract is a preliminary disclosure, not a publication, and the evidence for treating it cautiously is quantitative: in a Journal of Clinical Oncology study of 74 phase III abstracts presented at the 2000 ASCO Annual Meeting, 74% had corresponding journal publications six years…
The University of Minnesota has quadrupled its biomanufacturing capability with a new facility on its St. Paul campus, per the university's August 14, 2026 announcement. Minnesota Biomanufacturing Services, formerly the Biotechnology Resource Center, is five times larger than its predecessor…
PacBio (NASDAQ: PACB) announced on August 5, 2026 that SPRQ-Nx chemistry will raise per-run HiFi output on its Vega benchtop sequencer from 60 Gb to 90 Gb, per the company's press release. The U.S. list price per run drops from $1,100 to $995. A software update adds two-hour and four-hour run…
SOPHiA GENETICS (NASDAQ: SOPH) and AstraZeneca (LSE/STO/NYSE: AZN) have signed a multi-year global collaboration, announced August 4, 2026, to develop, validate, and deploy two companion diagnostics for AstraZeneca precision oncology therapies, per the companies' announcement. One program…